StockNews.com started coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC – Free Report) in a research note issued to investors on Tuesday morning. The brokerage issued a sell rating on the biotechnology company’s stock.
Cyclacel Pharmaceuticals Trading Down 4.4 %
Shares of CYCC stock opened at $0.83 on Tuesday. The company has a market capitalization of $1.79 million, a price-to-earnings ratio of -0.05 and a beta of 0.51. Cyclacel Pharmaceuticals has a 1-year low of $0.75 and a 1-year high of $10.12. The stock’s fifty day simple moving average is $1.04 and its 200-day simple moving average is $1.56.
Cyclacel Pharmaceuticals (NASDAQ:CYCC – Get Free Report) last issued its earnings results on Wednesday, August 14th. The biotechnology company reported ($0.72) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.11. Cyclacel Pharmaceuticals had a negative return on equity of 1,901.11% and a negative net margin of 21,963.75%. During the same period in the prior year, the business posted ($6.60) EPS. On average, sell-side analysts predict that Cyclacel Pharmaceuticals will post -2.29 EPS for the current year.
Hedge Funds Weigh In On Cyclacel Pharmaceuticals
About Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.
Featured Articles
- Five stocks we like better than Cyclacel Pharmaceuticals
- Quiet Period Expirations Explained
- Texas Roadhouse Stock Steering for New Highs This Year
- What Are Dividend Champions? How to Invest in the Champions
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- 3 Monster Growth Stocks to Buy Now
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for Cyclacel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.